Isishwankathelo | Ukufunyanwa kwe-antibody engathathi hlangothi ngokuchasene ne-bursa eyosulelayo ye-Fabricius virus kwi-serum yenkukhu |
Iinjongo zokuFumana | I-antibody yentsholongwane yesifo se-bursal yenkukhu |
Isampulu | ISerum
|
Ubungakanani | Ikhithi e-1 = 192 Uvavanyo |
Uzinzo kunye noGcino | 1) Zonke ii-reagents kufuneka zigcinwe kwi-2 ~ 8℃.Musa ukuba ngumkhenkce. 2) Ubomi beShelf ziinyanga ezili-12.Sebenzisa zonke ii-reagents phambi komhla wokuphelelwa kwekhithi.
|
Isifo se-bursal esosulelayo(IBD), ekwaziwa ngokuba sisifo seGumboro, i-infectious bursitis kunye ne-infectious avian nephrosis, sisifo esosulelayo kakhulu kulutsha.iinkukhukunye neeturkeys ezibangelwa yi-infectious bursal disease virus (IBDV), ephawulwa yiimmunosuppressionkunye nokufa ngokubanzi kwi-3 ukuya kwiiveki ezi-6 ubudala.Esi sifo safunyanwa okokuqala kwiGumboro, DelawareNgo-1962. Kubalulekile kwezoqoqosho kushishino lweenkukhu kwihlabathi jikelele ngenxa yokwanda kokuchaphazeleka kwezinye izifo kunye nokuphazamiseka okungalunganga kokusebenza.ugonyo.Kwiminyaka yakutshanje, iintlobo eziyingozi kakhulu ze-IBDV (vvIBDV), ezibangela ukufa okukhulu kwinkukhu, ziye zavela eYurophu,ilatin America,UMzantsi-mpuma weAsia, Afrika kunye nePhakathi empuma.Usulelo lwenziwa ngendlela ye-oro-fecal, apho intaka echaphazelekayo ikhupha amanqanaba aphezulu entsholongwane kangangeeveki ezi-2 emva kosulelo.Esi sifo sisasazeka ngokulula ukusuka kwiinkukhu ezosulelekileyo ukuya kwiinkukhu ezisempilweni ngokutya, amanzi, kunye nokudibana ngokomzimba.
Ikiti isebenzisa indlela ye-ELISA ekhuphisanayo, i-virus ye-virus ye-bursal efakwe ngaphambili kwi-microplate, kwaye ikhuphisane ne-anti-VP2 yeprotheyini ye-antibody kwi-serum ye-vector yesigaba esomeleleyo usebenzisa i-anti-VP2 protein monoclonal antibody.Kuvavanyo, i-monoclonal antibody eza kuvavanywa kwaye i-anti-VP2 protein yongezwa, kwaye emva kokufukanyelwa, ukuba isampulu iqulethe intsholongwane yesifo se-bursal yenkukhu eyosulelayo i-VP2 iprotein-specific antibody, ibophelela kwi-antigen kwipleyiti egqunyiweyo.Ngaloo ndlela ukuthintela ukubophelela kwe-anti-VP2 ye-protein ye-monoclonal antibody kwi-antigen, emva kokuhlamba ukususa i-anti-unbound and other components;emva koko ungeze i-anti-mouse enzyme-ebhalwe i-antibody yesibini ukuze ibophe ngokuthe ngqo kwi-antigen-antibody complex kwipleyiti yokufumanisa;I-conjugate ye-enzyme engabotshwanga isuswa ngokuhlamba;i-substrate ye-TMB yongezwa kwi-microwell ukuphuhlisa umbala, kwaye ixabiso lokufunxa isampuli lihambelana kakubi nomxholo we-anti-VP2 yeprotheyini ye-antibody equlethwe kuyo, ngaloo ndlela ifezekisa injongo yokufumanisa i-anti-VP2 yeprotheni ye-antibody kwisampuli.
I-Reagent | Umthamo Iimvavanyo ezingama-96/192Uvavanyo | ||
1 |
| 1ea/2ea | |
2 |
| 2.0ml | |
3 |
| 1.6ml | |
4 |
| 100ml | |
5 |
| 100ml | |
6 |
| 11/22ml | |
7 |
| 11/22ml | |
8 |
| 15ml | |
9 |
| 2ea/4ea | |
10 | i-serum dilution microplate | 1ea/2ea | |
11 | Umyalelo | iipcs ezi-1 |